|
|
Article: NEUROCRINE GETS POSITIVE DATA IN 'MOST IMPORTANT' INDIPLON STUDIES.
- Article from:
- BIOWORLD Today
- Article date:
- March 25, 2004
- Author:
CopyrightCOPYRIGHT 2004 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Kim Coghill, Washington Editor
Neurocrine Biosciences Inc. released favorable data from two long- term Phase III studies proving that its insomnia candidate, indiplon, remains effective for at least three months and is associated with quality-of-life improvements for its users.
The two trials, referred to as "RESTFUL" and "SLEEP," conclude an 11-trial Phase III program sponsored by San Diego-based Neurocrine and its partner, New York-based Pfizer Inc. The program database includes 5,000 patients and confirms that indiplon can improve sleep in patients with transient and chronic insomnia, the company said.
Neurocrine's stock ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|